AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04029740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT- both internet and face to face
Description: There are a few common psychotherapies for treating PD, with Cognitive Behavioral Therapy (CBT) as the most common. The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks (D H Barlow, 1997). The ICBT therapy is based on Barlow and Craske's (2007) protocol for treating PD with elaborations (Huppert \& Baker-Morissette, 2003). It includes six modules containing psychoeducation, cognitive restructuring, exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module, participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress.
Study NCT04029740 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Healthy controls will not receive any intervention.
Study NCT04510337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard rocuronium dose
Description: 0.6 mg/kg rocuronium during induction of anesthesia
Study NCT04510337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: 50 mg/kg magnesium sulphate added to 0.40 mg/kg rocuronium
Study NCT01562743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: Tansdermal patch
Study NCT03454243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXDX-106
Description: Patients will receive continuous daily oral doses of RXDX-106 in 21 day cycles. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), study drug will be administered in an escalated fashion starting at dose of 10 mg/day and will proceed at the dose levels prespecified by the dose escalation schema. Once daily dosing for RXDX-106 will initially be tested. However, other dosing schedules (eg, every other day, weight based, etc) may be tested based on safety and PK data to optimize drug exposure.
Study NCT03667326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet
Description: Low dose aspirin, 81mg tablets, PO
Study NCT03667326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule, PO
Study NCT00423644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darinaparson
Description: 420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months
Study NCT00367237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab + methotrexate (IFX + MTX)
Description: Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.
Study NCT00367237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (MTX)
Description: Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
Study NCT02368886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: Given topically
Study NCT02368886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02368886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02368886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study NCT02728219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: In this study we prospectively select some early diagnosed recurrent HCC patients after radical resection with AFP conversion, then they will be treated with transcatheter arterial chemoembolization (TACE)
Study NCT02728219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatectomy
Description: Repeat Hepatectomy after postoperation recurrence
Study NCT02512146 — intervention group
Intervention type: PROCEDURE
Intervention: colonoscopy
Description: Patients will undergo colonoscopy and participants will get biopsies from the colon.
Study NCT03415022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-based treatment
Description: 30 minute sessions of free viewing of faces and listening to music
Study NCT02205879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Study NCT02205879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01996644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vs Setraline
Description: Placebo
Study NCT01996644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setraline
Description: 250mg DCS
Study NCT02677246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab, one sub-cutaneous infusion, given within 2 weeks after engraftment defined as neutrophils > 0,5x10(9)/L and chimerism ≥ 10% of donor origin.~Before starting Denosumab several requirements have to be met: 1) Calcemia and Phosphatemia in the normal ranges, 2) adequate Calcium and Vitamin D intakes according to age.~Biological activity of Denosumab measured by CTX blood level, expected to last for 4 to 6 months after one infusion.~Possibility of subsequent infusions at the same dose level, every 5 to 6 months, for patient remaining on corticotherapy, provided no DLT occurred and provided CTX blood level decreased under the required threshold, after the previous infusions of Denosumab
Study NCT02219828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: 2mg/Kg daily sc up to 100mgday as maximum dose
Study NCT02219828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04317768 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Basic oral health education and motivation
Description: Subjects will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.
Study NCT04317768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic oral health education and motivation
Description: Subjects will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.
Study NCT04317768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive oral health education and motivation
Description: Subjects will be educated and motivated by an intensive program consisting of verbal instructions, PowerPoint lectures, posters and live demonstrations about oral hygiene instructions and teaching the proper way to brush the teeth. These will be reinforced by the investigator at intervals of 1 week, 1 month, 3 months, 6 months and 1 year.
Study NCT01094743 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A prototype lens
Description: Silicone hydrogel contact lens
Study NCT01094743 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: lotrafilcon B lens
Description: Silicon Hydrogel contact lens
Study NCT01298609 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occipital Stimulation
Description: Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
Study NCT01298609 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Occipital Stimulation
Description: Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
Study NCT01429961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1\~14
Study NCT03033121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Study NCT00970411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN951
Description: Orally once daily administration
Study NCT01246648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: dental extraction and gingival epithelial biopsy
Study NCT01246648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsy
Description: dental extraction and gingival epithelial biopsy
Study NCT00839982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given PO
Study NCT00839982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given SC
Study NCT00003377 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Study NCT00003377 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel
Study NCT00003377 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: brachytherapy
Study NCT00003377 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study NCT03675711 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Midline
Description: Patient will receive a Midline catheter within 48h after disappearance of indication for CVC
Study NCT03675711 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC
Description: Patient will receive a standard PVC within 48h after disappearance of indication for CVC
Study NCT04541186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection
Study NCT04541186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT01878695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV/oral n-acetylcysteine
Study NCT01536782 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bolus
Description: The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly.
Study NCT01536782 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gravity
Description: The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly.
Study NCT01536782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump
Description: The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly.
Study NCT02335021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: 2 packets per 12 fl oz
Study NCT02335021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: equisweet to sucralose
Study NCT02335021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose + maltodextrin
Description: sucralose plus equicaloric (to sucrose) maltodextrin
Study NCT02335021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose + Sucrose
Description: half the amount of sucralose plus equicaloric sucrose
Study NCT01341080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 1mg twice daily for eight weeks after a one week dose escalation period.
Study NCT01341080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 1mg twice daily for eight weeks after a one week dose escalation phase.
Study NCT06204185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Locally delivered Metformin gel in the treatment of periodontitis patients
Study NCT06204185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel consist of drug without the active component.
Study NCT02202356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176
Study NCT02202356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02377219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hormonal and blood analysis
Study NCT01209676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCgp100 injection
Description: a monoclonal T cell receptor anti-CD3scFv fusion protein
Study NCT04437108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Li-SWT (suprapubic approach)
Description: The patient will be asked to lie in flat dorsal position. A commercially used gel for sonography will be applied to the suprapubic region. The applicator will be placed on suprapubic region with two fingers apart from the symphysis pubis tilting to 45°. Shock waves will be directed to 3 different sites; the midline (over the bladder dome) and 3 cm right and left to the midline (over bilateral bladder walls). The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
Study NCT04437108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Li-SWT (perineal approach)
Description: The patient will be asked to lie in lithotomy position. A commercially used gel for sonography will be applied to the perineum. The applicator will be placed on perineal region. Shock waves will be directed to 3 different sites: the midline and 2 cm above and below the midline. The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
Study NCT04437108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Li-SWT (combined approach)
Description: The patient will receive 3000 shocks; 1500 shocks through suprapubic approach (500 shocks per site) and another 1500 shocks through perineal approach (500 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
Study NCT04437108 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: The same technique of Li-SWT will be used but the applicator of the shock wave device will be turned off.
Study NCT04437108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin
Description: The patients will be treated by antimuscarinics (solifenacin) which are considered as the conventional treatment of storage symptoms after prostatectomy.
Study NCT01686932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: vildagliptin 50mg BID for 8 weeks
Study NCT01686932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: sitagliptin 100mg QD for 8 weeks
Study NCT01663337 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Description: CPT is a highly structured course of therapy that focuses primarily on the cognitive restructuring of trauma related beliefs.
Study NCT01663337 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention (RP)
Description: RP utilizes high-risk situation assessment/avoidance, drink refusal skills, assertiveness training,cognitive restructuring as well as other approaches to address issues of alcohol use/dependance.
Study NCT01941264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: community based screening and treatment
Description: Already described in intervention arm description.
Study NCT01287234 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiogram/SonR
Description: All patients will have an echocardiograph and SonR sensor readings
Study NCT04008862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partnership-based nursing practice
Description: Provided by clinical nurse specialists (n=2) and specialized nurses (n=3): i) Partnership-based theoretical nursing practice framework: Family involvement, living with symptoms and access to healthcare -primary goal of enhancement of the health experience. Key question: What are your main concerns about the health of the person with the lung disease? Followed by conversations: a) Existence of lung disease and symptoms that the patient has. b) Nature of disease, its management, quitting smoking, use of inhaler medications, utilization of health care, negative feelings and issues. Skills and motivation to undertake activities to maintain and improve well-being, skills in communication with family, relatives and health professionals. ii) Empirical knowledge about the nature of COPD, symptom management and palliative care and the GOLD clinical guidelines. iii) Patients are seen over an undefined time period in the out-patient clinic or at home depending on needs and capabilities.
Study NCT04260022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascentage Pharma HQP1351 bioavailable inhibitor
Description: HQP1351 taken by mouth every other day
Study NCT04260022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Administered in all patients as a continuous IV infusion at the dosage of 28μg daily (9μg daily for Cycle 1 Day 1 to Day 7).
Study NCT02558881 — intervention group
Intervention type: PROCEDURE
Intervention: Virtual colonoscopy
Study NCT02558881 — intervention group
Intervention type: PROCEDURE
Intervention: Colon capsule
Study NCT01280123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Oral capsules of Pioglitazone (15 mg capsules) either 15 mg/qd or 45 mg/qd~Subjects will titrate in a blinded fashion to 30 mg/day after 2 weeks and to 45 mg per day) 2 weeks later as tolerated.
Study NCT01280123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
Study NCT01600131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver problem-solving
Description: This is a problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.ciddr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
Study NCT01600131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: No intervention or treatment will be provided. The investigators will closely monitor the usual care that is provided to caregivers.
Study NCT00720239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taliderm wound healing dressing
Description: Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:~Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.~Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.~Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase.
Study NCT02713581 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Venous blood will be sampled for laboratory analyses (see outcomes).
Study NCT02206711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: Single dose of drug on Day 1
Study NCT00406315 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ziprasidone
Description: Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
Study NCT01671488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: ADXS11-001 will be given at a dose of 1x109 cfu intravenously once every 28 days for 4 total doses. All 4 doses of ADXS11-001 will be 1x109 cfu.
Study NCT01671488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days